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The methylerythritol phosphate (MEP) pathway is an essential metabolic pathway found in malaria 
parasites, but absent in mammals, making it a highly attractive target for the discovery of novel 
and selective antimalarial therapies. Using high-throughput screening, we have identified 2-phenyl 
benzo[d]isothiazol-3(2H)-ones as species-selective inhibitors of Plasmodium spp. 2-C-methyl-D-
erythritol-4-phosphate cytidyltransferase (IspD), the third catalytic enzyme of the MEP pathway. 
2-Phenyl benzo[d]isothiazol-3(2H)-ones display nanomolar inhibitory activity against P. falciparum and 
P. vivax IspD and prevent the growth of P. falciparum in culture, with EC50 values below 400 nM. In silico 
modeling, along with enzymatic, genetic and crystallographic studies, have established a mechanism-
of-action involving initial non-covalent recognition of inhibitors at the IspD binding site, followed by 
disulfide bond formation through attack of an active site cysteine residue on the benzo[d]isothiazol-
3(2H)-one core. The species-selective inhibitory activity of these small molecules against Plasmodium 
spp. IspD and cultured parasites suggests they have potential as lead compounds in the pursuit of novel 
drugs to treat malaria.
As the search for new antimalarial compounds has intensified, isoprenoid biosynthesis has emerged as an 
essential metabolic process that is sensitive to chemical inhibition and is thus a prominent candidate for drug 
intervention against the malaria parasite1–4. Isoprenoids represent a diverse class of natural products, which are 
essential for many cellular functions, including protein prenylation and electron transport5,6. The biosynthesis 
of isoprenoids requires the production of two building blocks: the universal five-carbon precursors, isopente-
nyl pyrophosphate (IPP) and its isomer dimethylallyl pyrophosphate (DMAPP)7. Mammals synthesize IPP and 
DMAPP via the well-studied, coenzyme-A dependent, mevalonate (MVA) pathway8. In contrast, eubacteria 
and plastid-containing eukaryotes, including Plasmodium spp. parasites, utilize the methylerythritol phosphate 
(MEP) pathway to generate isoprenoid precursors (Fig. 1)2,9. As the MVA and MEP pathways evolved inde-
pendently, these pathways remain chemically and enzymatically distinct, enabling parasite-specific inhibition 
with minimal risk of toxicity to human cells10.
Small molecule inhibitors have been described against many enzymes of the MEP pathway through a number 
of programs aimed to harness the commercial, agricultural, and clinical potential of MEP pathway inhibition1,11,12. 
To date, the best-characterized inhibitor of the MEP pathway is the phosphonic acid antibiotic, fosmidomycin 
(FSM), a potent in vitro inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (IspC), the first dedicated 
enzyme in the MEP pathway (Fig. 1)13. FSM has undergone Phase II clinical trials as a potential antimalarial 
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chemotherapeutic in combination with clindamycin and piperaquine14 and has therefore demonstrated the valid-
ity and safety of targeting MEP pathway enzymes as an antimalarial strategy15.
The second dedicated enzyme of the MEP pathway is 2-C-methyl-D-erythritol-4-phosphate cytidyltransferase 
(IspD), which catalyzes the condensation of methylerythritol phosphate (MEP) with cytidine triphosphate (CTP) 
to generate 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) and inorganic pyrophosphate7,16. We and 
others have previously reported small molecule inhibitors of IspD (1 and 2, Fig. 2), confirming that IspD homologs 
are amenable to chemical inhibition12,17,18. These IspD inhibitors have generally shown high-micromolar activity, 
although some herbicidal A. thaliana species-selective nanomolar templates have also been identified (3a and 3b, 
Fig. 2). More recently, a chemical rescue screen identified 4 (1R,3S-MMV008138) from the Medicines for Malaria 
Venture (MMV) “malaria box” as a potent inhibitor of P. falciparum IspD (PfIspD), showing nanomolar inhibi-
tion of recombinant enzyme activity and sub-micromolar inhibition of parasite growth (Fig. 2)19–22.
Here we report the discovery of a new series of antimalarial IspD inhibitors and determination of their mech-
anism of action. We have employed a combined approach of chemoinformatics and high-throughput enzymatic 
screening to identify a new, chemically distinct series of IspD enzyme inhibitors that inhibit P. falciparum growth 
through disruption of isoprenoid biosynthesis in the Plasmodium parasite. Following chemotype identification, 
we have further developed this series, building structure-activity relationship around the chosen chemical motif 
and improving drug-like inhibitor properties. Finally, we have employed a combination of molecular modelling 
studies, site-directed mutagenesis and structural elucidation to determine the molecular mechanism by which 
these compounds achieve enzyme inhibition. This work has identified a series of compounds that are chemically 
Figure 1. The non-mevalonate methylerythritol phosphate (MEP) pathway of isoprenoid biosynthesis. 
Chemical structures of the native substrates and products of each enzyme in the MEP pathway are 
depicted: 1-deoxy-D-xylulose-5-phosphate synthase (DOXP Synthase); 1-deoxy-D-xylulose-5-phosphate 
reductoisomerase (IspC); 2-C-methyl-D-erythritol-4-phosphate cytidyltransferase (IspD); 4-diphosphocytidyl-
2C-methyl-D-erythritol kinase (IspE); 2-C-methyl-D-eryth-ritol-2,4-cyclodiphosphate synthase (IspF); 
1-hydroxy-2-methyl-2-(E)-butenyl-4-diphosphate synthase (IspG); 4-hydroxy-3-methyl-2-(E)-butenyl-4-
diphosphate reductase (IspH).
Figure 2. Known IspD inhibitors. 
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tractable, possess drug-like properties, and show significant promise for development as novel and potent anti-
malarial chemotherapies.
Results
Identification and optimization of benzoisothiazolone PfIspD inhibitors. A high-through-
put screen (HTS) was developed to identify inhibitors of purified recombinant PfIspD. An assay protocol and 
chemoinformatics strategy (Methods: Chemoinformatics strategy) suitable for HTS were optimized and validated 
for screening with the Z’ ranging from 0.85 to 0.9523. With active compounds defined as displaying an PfIspD 
IC50 of < 20 μ M, a total of 208 hit compounds were identified from the HTS study, comprising over 10 structural 
chemotypes. Significantly, the 2-phenyl benzo[d]isothiazol-3(2H)-one (BITZ) chemotype was repeatedly identi-
fied within a number of hit structures, including 7, which exhibited a PfIspD IC50 value of 450 ± 79 nM (Table 1).
A number of analogs, based around 7, were synthesized to explore the structure-activity relationship around 
the BITZ chemotype and analyze the nature and tolerance of the IspD active site. The bi-aryl BITZ template 
was selected to enable structural and chemical modification to the C and D rings adjacent to the inhibitor core 
(8–13, Table 1) with the aims of varying lipophilicity, improving solubility, and introducing functionality to 
enhance potency at PfIspD. A representative four-step synthesis of target compounds is shown (Fig. 3) involv-
ing an acid-chloride mediated amide coupling of 2-(methylthio) benzoic acid and 3-iodoaniline, generating a 
(methyl-thio)benzamide, 5a24. Oxidation of 5a to the corresponding sulfoxide, 5b24, followed by Suzuki-Miyaura 
cross-coupling reactions25, using a range of para-substituted phenyl boronic acids, was employed to generate 
intermediates 5c–g. The methylsulfinyl benzamides, 5c–g, were cyclized using a thionyl chloride-mediated 
ring closure26 to give selected inhibitors 8–12. Inhibitor 13 was generated using an alternative three-step syn-
thesis where a stable and isolatable acid chloride was employed for the generation of the core BITZ motif 
(Supplementary Fig. F1).
Several compounds demonstrated low micromolar to nanomolar activity against P. falciparum and P. vivax 
IspD enzymes (Table 1), highlighting both the efficacy of these compounds and their potential to act as broad 
spectrum antimalarial agents. Overall, the series 8–13 demonstrated good correlation between PfIspD enzyme 
inhibition and inhibition of parasite growth (r2 = 0.91, Fig. 4).
Given the ongoing and widespread issues of drug resistance to P. falciparum, it is critical that existing 
drug-resistant parasites are not cross-resistant to novel therapies in development. Therefore, we evaluated the 
antimalarial potency of BITZ compounds against a series of lab-adapted field isolates of P. falciparum, including 
strains resistant to chloroquine, mefloquine and artemisinin. We find that 8 effectively inhibits the growth of 
three lines of drug-resistant P. falciparum parasites (Table 2). These studies demonstrate the promise of BITZ 
compounds to inhibit parasite growth in Plasmodium strains with acquired resistance against current antimalarial 
drugs.
R PfIspD IC50 (μM) (3D7) EC50 (μM) PvIspD IC50 (μM) ClogD Caq Sol. (μM)
7 * 0.45 ± 0.079 4.3 ± 0.180 0.045 ± 0.020 2.86 9.12
8 OMe 0.21 ± 0.089 0.92 ± 0.066 0.054 ± 0.003 4.72 1.40
9 Cl 0.073 ± 0.020 1.1 ± 0.160 0.057 ± 0.013 4.98 0.56
10 CF3 0.27 ± 0.015 0.65 ± 0.021 0.041 ± 0.018 5.26 0.38
11 0.44 ± 0.075 0.42 ± 0.006 0.062 ± 0.026 3.80 56.23
12 0.86 ± 0.11 0.32 ± 0.092 0.24 ± 0.10 4.64 1.86
13 0.40 ± 0.082 0.41 ± 0.082 0.050 ± 0.016 4.13 2.51
Table 1.  Chemical structures of 7–13 with corresponding inhibitory activity (mean and SEM; n ≥ 3) 
against PfIspD, P. falciparum growth in culture (strain 3D7), and PvIspD. ClogD and Caq Sol. calculated 
using algorithms from AstraZeneca54,55.
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In optimising BITZ compounds, it was noted that meta-aryl functionalization across the C-ring consist-
ently gave good levels of enzyme inhibition and that this substitution pattern is required to maintain potent 
PfIspD inhibitory activity. In comparison, para-substitution across the C-ring lowered activity for series ana-
logs, highlighting the importance of active site-inhibitor shape complementarity (Supplementary Table T1). 
Para-substitution within the D-ring, using electron releasing or withdrawing groups (8–10) was well tolerated, 
Figure 3. General synthetic strategy for inhibitors 8–12. (a) SOCl2 (3.0 eq), toluene, DMF, reflux, 2–3 hours: 
then 3-iodoaniline (1.2 eq), Et3N (2.0 eq), THF, 10 minutes at 0 °C, 20 hours at 22 °C; 98% yield. (b) NaIO4 in 
H2O (1.6 eq), MeOH, 50 °C, 4–5 hours; 96% yield. (c) Phenyl boronic acid (1.2 eq), K2CO3 (3.3 eq), [Pd(PPh3)4] 
(0.025 eq), H2O:THF (1:2), 80 °C, 18–22 hours; 80–87% yield. (d) SOCl2 (1.3 eq), DCM, 50 °C, 1.5 hours;  
35–74% yield.
Figure 4. Correlation of enzyme PfIspD enzymatic inhibition and anti-parasitic activity for inhibitors 
8–13. Dose-dependent inhibition of enzyme activity and P. falciparum parasite growth was measured for 8–13 
(Table 1) and half-maximal inhibitory concentrations determined prior to least-squares linear regression 
analysis (coefficient of determination, r2 = 0.91; GraphPad Prism). Mean values given with SEM; n ≥ 3.
P. falciparum strain Whole Cell Growth Inhibition EC50 (μM)
3D7 0.92 ± 0.066
D6 0.80 ± 0.12
7G8 1.02 ± 0.25
IPC 5202 1.38 ± 0.19
Table 2.  Inhibitory activity of 8 against drug-resistant P. falciparum parasites grown in culture (mean and 
SEM; ≥3). Strains: 3D7, pan-sensitive; D6, mefloquine-resistant56; 7G8, multidrug (chloroquine)-resistant57; 
IPC 5202, artemisinin-resistant58.
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with PfIspD IC50 values as low as 73 ± 20 nM and parasite EC50 of 1.1 ± 0.16 μ M, with P. vivax IspD (PvIspD) 
IC50 values of 57 ± 13 nM for the para-chloro analog 9. In order to enhance aqueous solubility, methylene-linked 
polar heterocyclic groups were incorporated, exemplified by 11–13. Inhibitor 11 showed a 100-fold increase in 
predicted aqueous solubility compared to 9, a reduction in ClogD from 4.98 to 3.80, and displayed nanomolar 
inhibitory activity against PfIspD, PvIspD, and cultured P. falciparum, demonstrating that inhibitor activity of this 
series can be maintained whilst enhancing drug-like properties.
BITZ compounds inhibit isoprenoid metabolism in malaria parasites. To establish that 
anti-parasitic activity was the result of methylerythritol phosphate (MEP) pathway inhibition, we performed 
targeted metabolic profiling of MEP pathway intermediates in parasites treated with our BITZ IspD-inhibiting 
compounds. Early ring-stage cultures of P. falciparum were treated with compound concentrations at ~5 times 
the IC50 of 8 for 10 hours and MEP pathway intermediates were quantified by LC-MS/MS analysis as described 
elsewhere27. Similar to the established MEP inhibitor, FSM, 8 produced a significant decrease in MEcPP levels 
(p = 0.004: Fig. 5); however, levels of the upstream metabolite, DOXP, were not affected by treatment with 8 
(p = 0.94: Fig. 5). These results mirror those seen under comparable treatment with the established IspC inhibitor, 
FSM19, and therefore confirm that BITZ compounds inhibit the MEP pathway at levels known to affect asexual 
parasite growth.
In malaria parasites, supplementation with the isoprenoid precursor, IPP, has been demonstrated to rescue 
MEP pathway dysfunction. For example, IPP supplementation has been shown to allow parasite growth during 
treatment with either the DXR inhibitor, fosmidomycin (FSM), or the IspD inhibitor, 1R,3S-MMV00813820,21,28. 
In order to determine whether BITZ inhibition was specific to activity against the MEP pathway, we tested for 
IPP rescue during treatment with compound 8. No rescue was observed (p = 0.75; Supplementary Table T2). The 
observed correlation between enzymatic inhibition and parasite growth inhibition (Fig. 4), as well as metabolic 
analysis (Fig. 5), suggest that growth inhibition under treatment with BITZ compounds involves inhibition of the 
IspD enzyme. However, this lack of rescue by IPP supplementation suggests that off-target activity also contrib-
utes to parasite growth inhibition.
BITZ compounds inhibit IspD enzymes through covalent active site modification. To gain 
insight into the mechanism of enzyme inhibition, we developed a PfIspD homology model19 based on an E. coli 
IspD (EcIspD) protein structure (PDB ID: 1I5229). Molecular docking of 8 clearly indicates that the inhibitor 
binds within the CTP substrate-binding pocket, placing the BITZ warhead proximal to the PfIspD active site 
cysteine-202 (Cys-202) residue. We therefore predicted that the thiol moiety of Cys-202 would likely react with 
the sulfur heteroatom of BITZ inhibitors, forming a covalent disulfide adduct, while the carbonyl oxygen would 
be within hydrogen bonding distance of the backbone nitrogen atoms of Gly-203 and Gly-204 (Fig. 6). Formation 
of the covalent adduct would occlude the active site, preventing natural substrate binding and render the PfIspD 
enzyme inactive. The active site Cys-202 residue is conserved in Plasmodium spp. IspD enzymes but not in bac-
terial homologs (Fig. 7a). BITZ compounds are found to be ineffective against EcIspD enzyme activity (Fig. 7d), 
thus supporting the proposed involvement of and specific requirement for this Cys-202 residue, which is not 
present in the E. coli enzyme.
Our modelling studies predicted that mutation of Cys-202 to an alanine (Ala) residue would decrease the 
sensitivity of PfIspD to this BITZ compound class. Indeed, introducing this PfIspD mutation resulted in a 6-fold 
decrease in sensitivity: [PfIspD-wt IC50 = 81 ± 13 nM, while PfIspD-C202A IC50 = 470 ± 39 nM] (Fig. 7b) follow-
ing prolonged (50 min.) incubations with 8. This clear sensitivity change underlines the importance of Cys-202 
Figure 5. BITZ compounds inhibit the MEP pathway in P. falciparum. P. falciparum cultures were treated 
with 5 μ M FSM or 3 μ M 8 for 10 hours. Levels of the MEP pathway metabolites, DOXP and MEcPP, were 
measured using LC-MS/MS and compared to the levels in untreated parasites. Mean and standard error 
values from 3 independent experiments displayed. Asterisks (*) indicate significance threshold (alpha) = 0.05. 
Significant decreases in MEcPP levels were observed under treatment with both FSM (p = 0.0038) and 
compound 8 (p = 0.0042).
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for inhibitor activity, but may reflect both a loss of covalent bond formation and a change in compound fit within 
the active site following introduction of this mutation to the inhibitor binding region.
Covalent inhibition is often marked by an increase in the apparent potency of an inhibitor over time, as irre-
versible associations are gradually made between the inhibitor and enzyme. To evaluate this premise with respect 
to our proposed mechanism of enzyme inhibition, PfIspD and various concentrations of 8 were pre-incubated 
prior to measurement of enzyme activity. As expected for covalent inhibition, the potency of 8 increased over 
time (PfIspD-wt IC50 = 330 ± 57 nM at five min. and 81 ± 13 nM at 50 min.; p = 0.0007; Fig. 7c) whereas no 
such substantial or significant change in PfIspD-C202A inhibition was observed over the same time period 
(PfIspD-C202A IC50 data of 860 ± 220 nM at five min. and 470 ± 39 nM at 50 min.; p = 0.32). These results high-
light the importance of the proposed covalent interactions with Cys-202 during inhibition of PfIspD by BITZ 
inhibitors.
Once an inhibitor-adduct has formed, increasing substrate concentration should not relieve covalent enzyme 
inhibition. Consistent with this model, the susceptibility of PfIspD-wt to inhibition by 8, following prolonged 
incubation, was not substantially affected by CTP substrate concentration (Fig. 8b). In contrast, inhibition by 8 
Figure 6. Inhibitor 8 modeled in the active site of PfIspD homology model, covalently bound at Cys-202. 
PfIspD active site rendered as a white surface. Residues predicted to interact with inhibitors (Gly-203 and Gly-
204, hydrogen bonds; Cys-202, disulfide adduct) are depicted as sticks (carbon, orange; oxygen, red; nitrogen, 
blue; sulfur, yellow). 8 displayed as sticks (carbon, grey; oxygen, red; nitrogen, blue; sulfur, yellow). Hydrogen 
bonds depicted as black, dotted lines (predicted hydrogen bond distance in Ångstroms). Image created using 
PyMOL Molecular Graphics System, Version 1.5.0.4, Schrodinger, LLC.
Figure 7. BITZ compounds inhibit PfIspD through disulfide bond formation. (a) Alignment of IspD 
homologs: active site Cys residue is conserved in Plasmodium spp. but is absent in bacterial orthologs that are 
insensitive to BITZ inhibitors. (b) Dose-dependent inhibition of purified recombinant PfIspD-wt compared 
to PfIspD-C202A on treatment with 8. Representative data shown; n ≥ 3. (c) Time-dependent changes in 
inhibition of recombinant PfIspD-wt enzyme activity following treatment with 8. Mean and SEM displayed; 
n ≥ 4 for each data point. (d) Dose-dependent inhibition of recombinant EcIspD-wt compared to EcIspD-A14C 
by 8. Representative data shown; n ≥ 3.
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was somewhat relieved under higher CTP concentrations over shorter incubation periods, as is typically observed 
for reversible competitive inhibitors (Fig. 8a). Together, these observations are consistent with relatively slow 
inhibitor-enzyme adduct formation within the CTP binding site, as predicted by our molecular docking model. 
Inhibition of PfIspD-C202A activity was not significantly affected by CTP concentrations over short or long incu-
bations with 8 (Fig. 8c,d), demonstrating that the CTP-site binding does not substantially contribute to inhibition 
of mutant PfIspD-C202A and suggests an independent mode of inhibition of PfIspD-C202A.
While both P. falciparum and P. vivax IspD homologs possess an active site Cys-202 residue, the correspond-
ing residue in bacterial IspD homologs is alanine (Ala) (Fig. 7a). In contrast to the inhibitory IspD activity shown 
by BITZ analogues at P. falciparum and P. vivax IspD homologs (Table 1), we found that recombinant EcIspD was 
highly resistant to inhibition by 8 (Fig. 7d). Therefore, to confirm the critical role of active site Cys residues in 
inhibition, we generated a variant EcIspD protein, in which the corresponding Ala residue was substituted with 
a Cys residue by introduction of the A14C mutation. EcIspD-A14C was rendered sensitive to 8, with an IC50 of 
440 ± 48 nM (Fig. 7d). EcIspD-A14C was crystallized in the presence of 5 mM of 8 (Supplementary Table T3), 
providing supportive structural data. While electron density corresponding to 8 was not observed, the resulting 
crystal structure revealed formation of a novel intramolecular bond, leading to occlusion of the CTP binding site, 
thus providing modest additional evidence for a temporary covalent interaction between the inhibitor and the 
Cys-14 residue (Supplementary Fig. F2).
Figure 8. Inhibition of recombinant PfIspD enzymes. (a) Treatment of PfIspD-wt with 8 at varying CTP 
concentrations shows the concentration of CTP substrate affects the strength of inhibition at early time 
points. Five min. IC50 values gave 120 ± 17 nM at 100 μ M CTP and 330 ± 57 nM at 400 μ M CTP; p = 0.04. 
Representative data shown; n ≥ 3. (b) Treatment of PfIspD-wt with 8 at varying CTP concentrations shows the 
concentration of CTP substrate does not affect the strength of inhibition following extended incubation. 50 min. 
IC50 values gave 49 ± 7.6 nM at 100 μ M CTP and 81 ± 13 nM at 400 μ M CTP; p = 0.17. Representative data 
shown; n ≥ 3. (c) Treatment of PfIspD-C202A with 8 at varying CTP concentrations shows the concentration 
of CTP substrate does not affect the strength of inhibition at early time points. Five min. IC50 values gave 
660 ± 130 nM at 100 μ M CTP and 860 ± 120 nM at 400 μ M CTP; p = 0.32. Representative data shown; n ≥ 3. 
(d) Treatment of PfIspD-C202A with 8 at varying CTP concentrations shows the concentration of the CTP 
substrate does not affect the strength of inhibition following extended incubation. 50 min. IC50 values gave 
414 ± 86 nM at 100 μ M CTP and 470 ± 39 nM at 400 μ M CTP; p = 0.57. Representative data shown; n ≥ 3.
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Discussion
The non-mevalonate (MEP) pathway of isoprenoid biosynthesis is highly desirable as a target for antimalar-
ial drug development, as the parasite-specific enzymes of this pathway do not have mammalian homologs. 
Since isoprenoid biosynthesis contributes to a number of essential cellular functions, MEP pathway function is 
required for asexual replication of Plasmodium spp. parasites. Despite the promise of new MEP pathway-targeting 
agents, few studies have explored the potential of targeting the second-dedicated enzyme of this pathway, 
2-C-methyl-D-erythritol-4-phosphate cytidyltransferase (IspD), for the purpose of antimalarial chemotherapy. 
We have previously established that the ISPD gene of P. falciparum is resistant to genetic disruption and that the 
PfIspD enzyme is amenable to small molecule inhibition19. We now report a new, structurally distinct class of 
PfIspD 2-phenyl benzo[d]isothiazol-3(2H)-one (BITZ) inhibitors with antimalarial activity, which were identi-
fied through a target-based high-throughput study.
We find that BITZ compounds inhibit IspD enzymatic activity of both P. falciparum and P. vivax and that 
the IspD-inhibitory activity and antimalarial efficacy of these compounds are correlated (Fig. 4). Furthermore, 
we find that treatment of P. falciparum with growth-inhibitory concentrations of BITZ compounds is sufficient 
to disrupt de novo production of isoprenoid precursors. These findings strongly indicate that BITZ compounds 
inhibit parasite growth, at least in part, through inhibition of cellular IspD, as predicted. Importantly, parasite 
strains resistant to current generation antimalarials do not possess cross-resistance to BITZ compounds.
Our studies staunchly suggest that these novel IspD-inhibiting BITZ compounds have a distinctive mecha-
nism of action that relies on the formation of a covalent enzyme-inhibitor adduct, with several lines of evidence 
supporting this mechanism of inhibition. First, BITZ inhibitors are competitive with CTP during short incuba-
tion periods but enzymatic inhibition cannot be out-competed following prolonged incubation of PfIspD with the 
inhibitor, suggesting that a covalent bond is likely formed. Importantly, molecular modelling implicates a specific 
residue, Cys-202, as a likely site of enzyme modification by BITZ compounds. Supporting this model, we find 
that mutation of Cys-202 to an alanine residue confers BITZ resistance to recombinant PfIspD enzyme (Fig. 7). 
In addition, we find that the bacterial IspD enzyme, EcIspD, which possesses an alanine at the analogous position 
to Cys-202, is insensitive to BITZ compounds, but can be rendered sensitive via replacement of the alanine resi-
due with cysteine. The proposed mechanism of enzyme inhibition thus provides an explanation for the marked 
species-selectivity of BITZ compounds and their inhibitory activity amongst IspD homologs, despite the overall 
sequence homology across this group of enzymes.
The demonstrated cysteine reactivity of our BITZ compound series suggests that development of this series 
may be hampered by possible polypharmacology. However, several recent reviews have noted that covalent mech-
anisms of action are prevalent among successful drugs30,31. Indeed, aspirin, also a covalent modifier, is one of the 
most widely used drug in the world. The polypharmacology of bioactive molecules32,33 and approved drugs34 
has similarly been studied and is consistent with the concept that safe and effective drugs are invariably active at 
many targets. One such study calculates that, on average, approved therapeutics are active against approximately 
seven different molecular targets35. Since rescue with the isoprenoid precursor, IPP, is not observed, it is apparent 
that parasite growth inhibition by our BITZ compound series does not result solely from activity against IspD. 
Further studies may shed light on additional targets. Certainly continued vigilance will be required as BITZ com-
pounds and their derivatives progress in development, with continued monitoring for potential promiscuous and 
off-target reactivity that may lead to toxicity. However, it should be noted that, similar BITZ chemotypes have 
demonstrated successful medicinal chemistry optimisation36–42. Recently, a molecule containing a BITZ moiety 
has begun Phase II clinical trials as an antiviral agent, providing important evidence that the potential reactivity 
of the BITZ moiety alone is not incompatible with a safe therapeutic profile43.
In conclusion, we have identified novel PfIspD 2-phenyl benzo[d]isothiazol-3(2H)-one inhibitors, initiated 
from a HTS study. Following discovery of 7, several structural analogs were generated around the identified BITZ 
motif which display increased potency, both enzymatically and phenotypically, compared to the initial hit. We 
have shown that the BITZ motif and corresponding analogues act as potent PfIspD inhibitors and offer potential 
as a broad spectrum antimalarial agents. In addition, we have demonstrated that these compounds also express 
inhibitory activity against P. falciparum parasite strains which show drug resistance to existing antimalarial ther-
apies. Our studies clearly define the mechanism of inhibition of the BITZ chemotype and corresponding ana-
logues, with selectivity for PfIspD relying on the presence of an active site Cys residue. A mechanism of inhibition 
has been deciphered whereby a disulfide adduct is formed between PfIspD Cys-202 and the electrophilic sulfur 
atom of the BITZ inhibitor core. The next stages of hit development will focus on improving the efficacy, solubil-
ity, and PK properties of the most potent PfIspD inhibitors. The potential promiscuity of the BITZ warhead and 
possible binding events at additional protein contacts will also require careful consideration. However, as interest 
in the covalent modification of drug targets within drug design increases, similar techniques and experiments to 
those outlined here may be used to probe other identified Cys modifiers which may be capable of enacting this 
mode of covalent modification. As more researchers study the MEP pathway and screen for inhibitors of its dif-
ferent enzymes, expectations dictate that it will become a recognized target for the treatment of not just malaria, 
but also tuberculosis and other bacterial pathogens.
Methods
Chemoinformatics strategy. A chemoinformatics strategy was employed to identify possible inhibitors 
using known IspD substrates and inhibitors, metal binding moieties, and biphosphate isosteres as query mole-
cules for performing similarity and scaffold-hopping database searches44. A number of algorithms were applied, 
including molecular fingerprints45, turbo similarity46, principal component analysis, Bayesian modelling47, and 
machine learning to select ~10,000 compounds for screening. The selected structures were chosen from a com-
mercial library of ~500,000 compounds (BioFocus DPI) that were predicted to possess favorable absorption, 
distribution, metabolism, excretion, and toxicity characteristics48.
www.nature.com/scientificreports/
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Molecular Modelling. A homology model of PfIspD was constructed using the PHYRE online homology 
modelling program49. PfIspD primary sequence Q8I273 was obtained from UNIPROT (http://www.uniprot.
org/, accessed 10/12/14). A number of protein alignments and homology models were constructed by PHYRE, 
and the model with 98.82% confidence was selected, which was based on an E. coli IspD structure (PDB acces-
sion code 1I52)29. 1I52 is a 1.50-Å resolution crystal structure of E. coli IspD, complexed with CDP-ME in the 
active site. The structure of the model was validated using the WHATIF web interface50. 8 and other BITZ inhib-
itors were modelled in silico using the homology model described above in order to visualize the interactions 
between each analogue and the active site. Using GOLD, protons were added and docking was performed with 
default parameters, except that GoldScore was used and 50 docking poses were obtained for comparison and 
analysis. Covalent docking was performed using GOLD with the C-alpha atom of Cys-202 as the link atom to 
BITZ inhibitor 851.
Purification of IspD proteins. Plasmids derived from pBG1861, containing wildtype or mutant alleles of 
Plasmodium spp. or E. coli IspD, were used to transform Artic Express (DE3) RIL E. coli cells (Stratagene). Cells 
were grown in LB broth with 100 μ g/mL ampicillin at 37 °C and 200 rpm. During mid-logarithmic growth, cul-
tures were cooled to 8 °C, and protein expression was induced with 1 mM IPTG for 16 hours.
After induction, cell pellets were lysed by sonication in lysis buffer (25 mM Tris pH 7.5, 250 mM NaCl, 1 mM 
MgCl2, 1 mM dithiothreitol (DTT), 20 mM imidazole, 10% glycerol, 0.1% Triton X-100, 200 μ M PMSF, 1 mg/mL 
lysozyme, 0.3 U/mL benzonase nuclease (Novagen), and Roche Complete EDTA-free protease inhibitor). 
6His-tagged IspD proteins were purified from soluble lysate over Ni-NTA resin (Goldbio). Beads were washed 
with 250 mM NaCl, 25 mM Tris pH 7.5, 1 mM MgCl2, 20 mM imidazole, and protein was eluted with 250 mM 
NaCl, 25 mM Tris pH 7.5, 1 mM MgCl2, 300 mM imidazole. Affinity purification of PvIspD proceeded similarly 
to PfIspD purifications, except that 0.1% Triton X-100 and 10% glycerol were not present in the lysis buffer. 10% 
glycerol was also absent from the lysis buffer used in purifying wildtype and A14C E. coli IspD, and lysis buffer 
used in purifying wildtype and C202A PfIspD used in mechanistic studies (Figs 7 and 8).
Affinity-purified proteins were further purified over a HiLoad 16/60 Superdex 200 gel filtration column (GE 
Health Sciences), using an AKTA Explorer 100 FPLC (GE Health Sciences). FPLC buffer contained 250 mM 
NaCl, 25 mM Tris pH 7.5, 1 mM MgCl2. Fractions containing purified protein (> 90% pure as evaluated by 
SDS-PAGE) were pooled and concentrated by centrifugation using Amicon Ultra-15 Centrifugal Filter Units 
(EMD Millipore). Concentrated protein was supplemented with 10% glycerol and 1 mM DTT (although DTT 
was omitted from wildtype and C202A PfIspD preparations used in mechanism of action studies, (Figs 7 and 8), 
flash-frozen in liquid nitrogen, and stored at − 80 °C. Protein concentration was measured using a BCA protein 
assay kit (Thermo Scientific).
MEP metabolite profiling. Prior to treatment, parasites were synchronized by 1–2 treatments with 5% 
sorbitol until > 8% parasitemia and > 75% ring-stage cultures were achieved. At this point, cultures were treated 
10 hours with 5 μ M compound 8, 5 μ M fosmidomycin, or left untreated. Following treatment, parasite-infected 
erythrocytes were lysed with 0.1% saponin, washed in phosphate-buffered saline, and stored at − 80°C until 
extraction and quantitative LC-MS/MS measurement of DOXP and MEcPP, as previously described. Values 
reflect the mean and standard error from ≥ 3 independent experiments and were compared using the Student’s 
t-test (two-tailed).
Cloning of PfIspD and orthologs. P. falciparum: The construct used for expression of the codon-optimized 
PfIspD protein has been described previously19. To generate the PfIspD variants containing the C202A muta-
tion, N- and C-terminal fragments of the optimized PfISPD gene were amplified from the above vector using 
the following primers. C202A N-terminal fragment: T7 Fwd primer, 5′ -TAATACGACTCACTATAGGG-3′ , 
with C202A Rev primer, 5′ -GTTTGCCAATACCGCCGGCTAGCAGGATACTATGAATG-3′ ; C202 C-terminal 
fragment, C202A Fwd primer, 5′ -CATTCATAGTATCCTGCTAGCCGGCGGTATTGGCAAAC-3′ , with T7 
Rev primer, 5′ -GCTAGTTATTGCTCAGCGG-3′ . Amplicons containing the entire PfISPD gene were generated 
using PfIspD Fwd and Rev primers, which introduce a 6-His tag, with N- and C-terminal fragments as template 
(PfIspD Fwd primer: 5′ -CTCACCACCACCACCACCATATGATGCACATCTACGATAATAATAA-3′ ; PfIspD 
Rev: 5′ -ATCCTATCTTACTCACTTATTTTGAGGAGTAGTAGAAT-3′ ). Following amplification, PfISPD var-
iants were cloned into pBG1861 by ligation-independent cloning as previously described19,52, and verified by 
Sanger sequencing.
P. vivax: The construct used for expression of codon-optimized PvIspD (P. vivax Sal-1; PVX_081425) has been 
previously described19.
E. coli: The construct used for expression of EcIspD-wt has been previously described27. The A14C mutation was intro-
duced by first generating N- and C-terminal gene fragments containing the mutation. These fragments were generated 
using the following primers: A14C N-terminal fragment: T7 Fwd primer, 5′-TAATACGACTCACTATAGGG-3′, with 
A14C Rev primer, 5′-CATTCGACGGCCAAATCCGGCACACGGAACCACGGCGCAAACATC-3′ ; A14C C-terminal 
fragment, A14C Fwd primer, 5′ -GATGTTTGCGCCGTGGTTCCGTGTGCCGGATTTGGCCGTCGAATG-3′ , with 
T7 Rev primer, 5′ -GCTAGTTATTGCTCAGCGG-3′ . Amplicons containing the entire E. coli IspD gene were gener-
ated using EcIspD Fwd and Rev primers, which introduce a 6-His tag, with N- and C-terminal fragments as template 
(EcIspD Fwd primer: 5′ -CTCACCACCACCACCACCATATGATGGCAACCACTCATTTGG-3′ ; EcIspD Rev primer: 
5′ -ATCCTATCTTACTCACTTATTTGTATTCTCCTGATGG-3′ ). Following amplification, E. coli A14C-IspD was 
cloned into pBG1861 by ligation-independent cloning as previously described52, and verified by Sanger sequencing.
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IspD assay conditions. Phosphate released by IspD was quantified using the EnzChek Phosphate Assay 
Kit (Invitrogen, Life Technologies), as previously described27. 2-Amino-6-mercapto-7-methylpurine riboside 
(MESG) and purine nucleoside phosphorylase (PNP) were diluted and stored according to the manufacturer’s 
instructions. Final concentrations of reagents were as follows: 100 mM NaCl, 25 mM Tris pH 7.5, 7.5 mM MgCl2, 
1 U/ml PNP, 0.1 U/mL yeast inorganic pyrophosphatase (New England Biolabs). Unless otherwise specified, IC50 
assays contained 50 nM enzyme, 400 μ M CTP (Sigma), 200 μ M MEP (Echelon Biosciences), 2% DMSO (vehicle), 
and 200 μ M MESG. Reactions were performed in 50 μ L final volumes in 96-well clear flat bottom plates. In general, 
enzymes, buffers, and inhibitors were pre-warmed approximately 15 minutes at 37 °C, and reactions were then ini-
tiated by addition of the MEP substrate. Timed inhibitor 8 IC50 assays (5, 20, 35, and 50 minute incubations) and 
comparisons between behavior at 100 μ M and 400 μ M CTP were initiated by the addition of the CTP substrate and 
contained 100 nM enzyme. Assays using E. coli IspD used 7.5 nM EcIspD-wt or 75 nM EcIspD-A14C. Absorbance 
at 360 nm was measured over time on a BMG POLARStar plate reader, preheated to 37 °C. Nonlinear regression 
analysis was performed using GraphPad Prism software. Values reflect the mean and standard error from ≥ 3 
independent experimental and were compared using the Student’s t-test (two-tailed). Slopes of changing absorb-
ance values were converted to (μ M MEP) (μ M enzyme)−1 s−1 using a phosphate standard curve.
P. falciparum culture. Unless otherwise specified, P. falciparum parasites were cultured as previously 
described6,53, in a 2% suspension of human erythrocytes in RPMI-1640 medium (Sigma Aldrich) supplemented 
with 27 mM sodium bicarbonate, 11 mM glucose, 5 mM HEPES, 1 mM sodium pyruvate, 0.37 mM hypoxan-
thine, 0.01 mM thymidine, 10 μ g ml−1 gentamicin and 0.5% Albumax (Life Technologies). Cultures were main-
tained in 5% O2/5% CO2/90% N2 at 37 °C. Parasite growth was monitored by microscopy of Giemsa-stained 
parasites. 3D7 strain parasites were obtained from the Malaria Research and Reference Reagent Resource Center, 
ATCC, Manassas, Virginia. D6 and 7G8 strains were obtained through BEI Resources Repository, NIAID, 
NIH: Plasmodium falciparum, Strain D6, MRA-285, contributed by D.E. Kyle; Plasmodium falciparum, Strain 
7G8, MRA-152, contributed by David Walliker. The IPC 5202 strain was provided by the Malaria Research and 
Reference Reagent Resource Center (MR4) for distribution by BEI Resources NIAID, NIH: Plasmodium falci-
parum, Strain IPC 5202, also known as CAM3.IR539T; MRA-1240, contributed by Didier Ménard.
Parasite sensitivity assays. Asynchronous cultures of P. falciparum strain 3D7 were diluted to 1% par-
asitemia and cultured at indicated concentrations of inhibitor compounds in 100 μ L culture volumes. During 
rescue experiments, parasite growth medium was supplemented with 200 μ M isopentenyl pyrophosphate (IPP; 
Echelon Biosciences). After 72 hours, parasite growth was quantified using PicoGreen dye (Invitrogen) to meas-
ure DNA content as previously described27. PicoGreen fluorescence was measured (485 nm excitation/528 nm 
emission) in a POLARStar Omega microplate reader (BMG Labtech). IC50 values were calculated by nonlinear 
regression analysis using GraphPad Prism software, and reflect the mean and standard error from ≥ 3 independ-
ent experiments. Values were compared using the Student’s t-test (two-tailed).
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